SCHEMBL1864575

SCHEMBL1864575

O=C(O)C1[CH]CCCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1868510 1.00
SCHEMBL1864577 1.00
SCHEMBL5966226 0.98 POLB (0.36)
SCHEMBL20295933 0.92
SCHEMBL360829 0.92
SCHEMBL20295697 0.92
SCHEMBL5966260 0.84
SCHEMBL5482159 0.81 POLB (0.34)
SCHEMBL11384229 0.79 KDM4E (0.34)
SCHEMBL11384206 0.79 KDM4E (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 567 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117983302-A Catalyst containing ferrocene PNP ligand for ethylene selective tetramerization and preparation method and application thereof 华东理工大学 2024-05-07 CN claimed
US-20230122243-A1 Heteroaromatic inhibitors of astacin proteinases VIVORYON THERAPEUTICS N.V. (DE) 2023-04-20 US claimed
CN-114585608-A Heteroaromatic inhibitors of astacin protease 维沃永治疗公众有限公司 2022-06-03 CN claimed
EP-3986868-A1 HETEROAROMATIC INHIBITORS OF ASTACIN PROTEINASES Vivoryon Therapeutics N.V. (DE) 2022-04-27 EP claimed
WO-2020249760-A1 HETEROAROMATIC INHIBITORS OF ASTACIN PROTEINASES VIVORYON THERAPEUTICS AG (DE) 2020-12-17 WO claimed
US-20170189443-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) 2017-07-06 US claimed
CN-106456662-A Compositions of pentosan polysulfate for oral administration and methods of use thereof 奥利金制药公司 2017-02-22 CN claimed
EP-3110427-A1 COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE Urigen Pharmaceuticals, Inc. (US) 2017-01-04 EP claimed
WO-2015127416-A1 COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE URIGEN PHARMACEUTICALS, INC. (US) 2015-08-27 WO claimed
US-20130150323-A1 USE OF ORAL HEPARIN PREPARATIONS TO TREAT URINARY TRACT DISEASES AND CONDITIONS Urigen Pharmaceuticals, Inc (US) 2013-06-13 US claimed
WO-2005113582-A1 SUBSTITUTED ETHANE-1,2-DIAMINES FOR THE TREATMENT OF ALZHEIMER'S DISEASE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-12-01 WO claimed
CN-1190893-A Compounds and compositions for delivery of active agents EMISPHERE TECH INC (US) 1998-08-19 CN claimed
EP-0654995-B1 4-OXA-1-AZABICYCLO (3,2,0) HEPTAN-7-ONE DERIVATIVES AS ANTITUMOR AGENTS TAIHO PHARMACEUTICAL CO LTD (JP) 1996-10-23 EP claimed
US-5561126-A OXAPENAMS HAVING CHEMICAL STABILITY; ANTICARCINOGENIC AGENTS; LEUKEMIA TAIHO PHARMACEUTICAL CO., LTD. (JP) 1996-10-01 US claimed
EP-0654995-A1 4-OXA-1-AZABICYCLO (3,2,0) HEPTAN-7-ONE DERIVATIVES AS ANTITUMOR AGENTS. TAIHO PHARMACEUTICAL CO LTD (JP) 1995-05-31 EP claimed
US-5362559-A Improved strength and uniformity KABUSHIKI KAISHA TOSHIBA (JP) 1994-11-08 US claimed
CN-1082548-A Antineoplastic agent 4-oxa--1-azabicyclo [3,2, O] heptane-7-ketone derivatives MEDICINE BIOLOG TECH I CHINA M (CN) 1994-02-23 CN claimed
WO-1994001109-A1 4-OXA-1-AZABICYCLO [3,2,0] HEPTAN-7-ONE DERIVATIVES AS ANTITUMOR AGENTS TAIHO PHARMACEUTICAL CO. LTD. (JP) 1994-01-20 WO claimed
EP-0470543-A1 Heterocyclic imidazoles, remedies containing them and processes for their preparation Dr. Karl Thomae GmbH (DE) 1992-02-12 EP claimed
CN-1046893-A PROCESS FOR PREPARATION OF 2-CYCLOHEXYL CARBOXYLATES RHONE POULENC CHIMIE (FR) 1990-11-14 CN claimed